Moreover, increased Ang2 levels were observed in patients with NASH and advanced liver fibrosis, and the inhibition of Ang2 by antibodies or small molecules could restore liver fibrosis in mouse models [35,39]. Here, ANGPT2 is linked to metabolic dysfunction-associated steatohepatitis.